ClinicalTrials.gg
Status unknownNCT04291794Updated Mar 2, 2020

Mean Arterial Pressure Reduction Anesthesia Induction Using Propofol Bolus or Tritiated Target-infusion

A Phase 4 interventional study of Propofol and Propofol Injection [Diprivan] in Hypotension on Induction and Hypnotic Intoxication, sponsored by Brasilia University Hospital. Status unknown at 1 site in Brazil. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-02.

Sponsored by Brasilia University Hospital · Phase 4, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Feb 2020), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To compare haemodynamics and bispectral index values between conventional bolus propofol induction and target-controlled propofol infusion.

Read the detailed description

To compare mean arterial pressure, heart rate and bispectral index values between conventional bolus propofol induction and target-controlled propofol infusion.

02

Conditions studied

  • Hypotension on Induction
  • Hypnotic Intoxication

Browse trials for

03

In context

Hypotension

885 studies on the registry are indexed under Hypotension; 195 are open to participants now.

This study's planned enrollment of 120 is above the median of 87 across 590 interventional studies indexed under Hypotension.

Browse Hypotension studies →

Lead sponsor

Brasilia University Hospital is the lead sponsor of 20 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Scheduled for general anesthesia;
  • No for propofol.

Exclusion criteria

Exclusion Criteria:

  • Data loss;
  • Protocol violation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Conventional bolus induction

    Hypnotic component of general anesthesia induction will be a single bolus of propofol 2mg/kg followed by turning on sevoflurane 2% at a fresh gas flow of 2L/min.

    Drug: Propofol

  • Experimental
    Target-controlled induction

    Hypnotic component of general anesthesia induction will be target-controlled propofol infusion tritiated to loss of consciousness. Propofol target-controlled infusion will be maintained.

    Drug: Propofol Injection [Diprivan]

Interventions

06

What researchers measure

Primary outcomes

  1. Mean arterial pressure after 2 minutes

    Mean arterial pressure using non-invasive device

    Time frame: 2 minutes after general anesthesia induction

  2. Mean arterial pressure after 4 minutes

    Mean arterial pressure using non-invasive device

    Time frame: 4 minutes after general anesthesia induction minutes after general anesthesia induction

  3. Mean arterial pressure after 6 minutes

    Mean arterial pressure using non-invasive device

    Time frame: 6 minutes after general anesthesia induction minutes after general anesthesia induction

  4. Mean arterial pressure after 8 minutes

    Mean arterial pressure using non-invasive device

    Time frame: 8 minutes after general anesthesia induction minutes after general anesthesia induction

  5. Mean arterial pressure after 10 minutes

    Mean arterial pressure using non-invasive device

    Time frame: 10 minutes after general anesthesia induction minutes after general anesthesia induction

Secondary outcomes

  1. Heart Rate after 2 minutes

    Heart rate (pulse rate) using non-invasive device.

    Time frame: 2 minutes after general anesthesia induction

  2. Heart Rate after 4 minutes

    Heart rate (pulse rate) using non-invasive device.

    Time frame: 4 minutes after general anesthesia induction

  3. Heart Rate after 6 minutes

    Heart rate (pulse rate) using non-invasive device.

    Time frame: 6 minutes after general anesthesia induction

  4. Heart Rate after 8 minutes

    Heart rate (pulse rate) using non-invasive device.

    Time frame: 8 minutes after general anesthesia induction

  5. Heart Rate after 10 minutes

    Heart rate (pulse rate) using non-invasive device.

    Time frame: 10 minutes after general anesthesia induction

  6. Bispectral Index after 2 minutes

    Bispectral Index (BIS) using non-invasive device. At values near 100 mean patient is more likely to be awake and at values below 60 are more likely to be under general anesthesia.

    Time frame: 2 minutes after general anesthesia induction

  7. Bispectral Index after 4 minutes

    Bispectral Index (BIS) using non-invasive device. At values near 100 mean patient is more likely to be awake and at values below 60 are more likely to be under general anesthesia.

    Time frame: 4 minutes after general anesthesia induction

  8. Bispectral Index after 6 minutes

    Bispectral Index (BIS) using non-invasive device. At values near 100 mean patient is more likely to be awake and at values below 60 are more likely to be under general anesthesia.

    Time frame: 6 minutes after general anesthesia induction

  9. Bispectral Index after 8 minutes

    Bispectral Index (BIS) using non-invasive device. At values near 100 mean patient is more likely to be awake and at values below 60 are more likely to be under general anesthesia.

    Time frame: 8 minutes after general anesthesia induction

  10. Bispectral Index after 10 minutes

    Bispectral Index (BIS) using non-invasive device. At values near 100 mean patient is more likely to be awake and at values below 60 are more likely to be under general anesthesia.

    Time frame: 10 minutes after general anesthesia induction

07

Study locations

1 site
  • Hospital Universitário de Brasilia
    Brasilia, Distrito Federal 70000000, Brazil
08

References and documents

Individual participant data

Plan to share: Yes — Plan to share at open database.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: After study ends

Access criteria: Open

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2020; primary completion for Sep 2020, 6 months later.

Of 60 non-industry phase 4 interventional studies under Hypotension, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's planned 6 months is below that.

Counting every sponsor, half of 61 studies reached it within 12 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2020
First posted
Mar 2, 2020
StartEst.
Mar 1, 2020
Primary completionEst.
Sep 25, 2020
CompletionEst.
Nov 27, 2020
Last update
Mar 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04291794
Lead sponsor
Brasilia University Hospital
Responsible party
Gabriel Magalhaes Nunes Guimaraes (Voluntary professor, Brasilia University Hospital) — Principal investigator
First posted
Mar 2, 2020
Start date
Mar 1, 2020 (estimated)
Primary completion
Sep 25, 2020 (estimated)
Completion
Nov 27, 2020 (estimated)
Last update
Mar 2, 2020

Study contacts

Gabriel MN Guimaraes, MSc
Contact
gabrielmng@gmail.com
+5561996455997
Gabriel MN Guimaraes, MSc
principal investigator · Professor

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Propofol

Start the discussion